

## **Administrative Details Regarding the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and the ACCORDION Study**

(September 25, 2015)

**ACCORD ClinicalTrials.gov Identifier: NCT00000620**

### **Funding Support**

ACCORD was supported by National Heart Lung and Blood Institute contracts N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, and IAA #Y1-HC-9035, and IAA#Y1-HC-1010. Other components of the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Eye Institute, contributed funding. The Center for Disease Control funded substudies within ACCORD on cost-effectiveness and health-related quality of life. General Clinical Research Centers provided support at many sites. This material is also the result of work supported with resources and the use of facilities at the Veterans Affairs medical centers as listed previously.\* ACCORDION activities were supported by National Heart Lung and Blood Institute Contract HHSN268201100027C. The contents do not represent the views of the NIH or the U.S. Department of Veterans Affairs or the United States Government.

### **Acknowledgements**

**Members** of the ACCORD Data Safety Monitoring Board (DSMB) were: Antonio M. Gotto, Jr. (chair), Kent Bailey, Dorothy Gohdes, Steven Haffner, Roland Hiss, Kenneth Jamerson, Kerry Lee, David Nathan, James Sowers, Leroy Walters.

Members of the ACCORDION Observational Study Monitoring Board (OSMB) were: Barbara V. Howard (chair), Kent R. Bailey, Richard Hamman, William Herman, Kenneth A. Jamerson, David M. Nathan, Alan Shuldiner.

During ACCORD, the following companies provided study medications, equipment, or supplies: Abbott Laboratories (Abbott Park, IL); Amylin Pharmaceutical (San Diego, CA); AstraZeneca Pharmaceuticals LP (Wilmington, DE); Bayer HealthCare LLC (Tarrytown, NY); Closer Healthcare Inc. (Tequesta, FL); GlaxoSmithKline Pharmaceuticals (Philadelphia, PA); King Pharmaceuticals, Inc. (Bristol, TN); Merck & Co., Inc. (Whitehouse Station, NJ); Novartis Pharmaceuticals, Inc. (East Hanover, NJ); Novo Nordisk, Inc. (Princeton, NJ); Omron Healthcare, Inc. (Schaumburg, IL); Sanofi-Aventis U.S. (Bridgewater, NJ); Schering-Plough Corporation (Kenilworth, NJ); Takeda Pharmaceuticals (Deerfield, IL).

\* Action to Control Cardiovascular Risk in Diabetes Study Group., Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-2559.